Lung Cancer News

Neoadjuvant nivolumab plus platinum-based chemotherapy conferred sustained clinical benefit for patients with resectable non-small cell lung cancer, 3-year follow-up results of the phase 3 CheckMate -816 trial showed.

Amivantamab-vmjw conferred long-term clinical response in patients with advanced non-small cell lung cancer and EGFR exon 20 insertion mutations, according to data from the agent’s manufacturer.

FDA granted full approval to pembrolizumab for treatment of certain adults and children with unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors as determined through an FDA-approved test.

Community oncologists who received peer coaching from cancer genetics experts more frequently ordered genetic testing for their patients, according to study results.

Overall treatment outcomes among patients with extensive-stage small cell lung cancer who received first-line chemoimmunotherapy appeared comparable to those reported in pivotal clinical trials, according to study results.

Patients with limited-stage small cell lung cancer who received higher-dose, once-daily radiotherapy achieved outcomes comparable to those who received the standard lower-dose, once-daily regimen, according to phase 3 study results.

Moderate to severe depression in patients with lung cancer was linked to elevated inflammation levels, and the biomarkers measuring inflammation predicted poor survival, according to study results published in PLOS ONE.

The concept of cancer vaccination has generated excitement in the scientific community for decades.

Major discrimination events appeared associated with increased frailty among Black survivors of various cancer types, according to study results published in Cancer.

Researchers at Cancer Care Alberta and University of Calgary have demonstrated the value of a cancer symptom algorithm in correctly identifying which patients may be at high risk for an unplanned ED visit.